CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BCAL Diagnostics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BCAL Diagnostics Ltd
Suite 506, Level 5, 50 Clarence Street
SYDNEY, NSW  2000  Australia Ticker: BDXBDX
Business Summary
BCAL Diagnostics Limited is an Australia-based screening and diagnostic company focused on early diagnosis of breast cancer. The Company’s core activity is the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, which is available to all women. It is developing diagnostic technology to assist in the early detection of breast cancer by identifying, measuring and validating specific biomarkers enriched in the patient’s blood. It is engaged in the research and development of non-invasive diagnostic technologies designed to complement existing imaging technologies, such as the mammogram. Its BCAL laboratory employs liquid chromatography mass spectrometry (LCMS) platforms to build on the Company's clinical research and leverage progress. The Company’s BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
3826 Laboratory analytical instruments

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board JayneShaw 2/15/2010 2/15/2010
Chief Executive Officer ShaneRyan 4/2/2024 9/21/2023
Chief Financial Officer, Company Secretary Guy A.Robertson 3/16/2021 3/16/2021
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 314,294,714 (As of 6/30/2024)
Shareholders: 771
Stock Exchange: ASX


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024